RenalytixAI will provide financial support to the University of Utah in the form of sponsored research into kidney disease progression, treatment, and biomarkers.
G+FLAS said it provides CRISPR-related research services, tools, and reagents and applies CRISPR technology to develop drugs and produce genome-edited plants.
A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
The platform, based on the firm's Hi-C technology, is designed to assembly viral genomes from metagenomic samples and associate them with their microbial hosts.
The Paris-based company plans to use the nucleic acid modification technology to synthesize qPCR probes for use in diagnostics, among other biomolecules.
Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.
The expanded partnership includes a commercial agreement for the ClonoSeq and ImmunoSeq assays, as well as a lab service agreement for the T-Detect COVID test.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.
The method could be used to determine the function of thousands of mutations to see whether they cause disease, or confer drug sensitivity or resistance.
The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.
The sequencing test involves a single library preparation that is then split for parallel analysis of promoter methylation, MSI calculation, and gene mutation detection.
Starting with a genome-wide association study focused on skin pigmentation, investigators identified genetic variants with additional ties to vitamin D levels.
Using technology rooted in pharmacogenomics testing for medical cannabis, the firm claims it can predict immune response to SARS-CoV-2 and test biomarkers for pharma.
Initial partners in the program include Thermo Fisher Scientific, GNS Healthcare, DNAnexus, Personal Genome Diagnostics, and the Wellcome Sanger Institute.
